JP2008535873A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535873A5 JP2008535873A5 JP2008505738A JP2008505738A JP2008535873A5 JP 2008535873 A5 JP2008535873 A5 JP 2008535873A5 JP 2008505738 A JP2008505738 A JP 2008505738A JP 2008505738 A JP2008505738 A JP 2008505738A JP 2008535873 A5 JP2008535873 A5 JP 2008535873A5
- Authority
- JP
- Japan
- Prior art keywords
- adrenergic receptor
- composition
- receptor agonist
- beta
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000048 adrenergic agonist Substances 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 22
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 21
- 239000003814 drug Substances 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- -1 C 1-6- Alkoxyl Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 238000011200 topical administration Methods 0.000 claims 6
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 5
- 125000002877 alkyl aryl group Chemical group 0.000 claims 4
- 206010025135 lupus erythematosus Diseases 0.000 claims 4
- 150000003254 radicals Chemical class 0.000 claims 4
- 150000001721 carbon Chemical group 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 229960002052 salbutamol Drugs 0.000 claims 3
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 2
- TWUSDDMONZULSC-QMTHXVAHSA-N (1s,2r)-2-(tert-butylamino)-1-(2,5-dimethoxyphenyl)propan-1-ol Chemical compound COC1=CC=C(OC)C([C@H](O)[C@@H](C)NC(C)(C)C)=C1 TWUSDDMONZULSC-QMTHXVAHSA-N 0.000 claims 2
- UWYLQWLJGMLJQF-UHFFFAOYSA-N 1-(4-aminophenyl)-2-(butan-2-ylamino)ethanol Chemical group CCC(C)NCC(O)C1=CC=C(N)C=C1 UWYLQWLJGMLJQF-UHFFFAOYSA-N 0.000 claims 2
- XTJMTDZHCLBKFU-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-fluorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1F XTJMTDZHCLBKFU-UHFFFAOYSA-N 0.000 claims 2
- BUXRLJCGHZZYNE-UHFFFAOYSA-N 2-amino-5-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzonitrile Chemical compound CC(C)NCC(O)C1=CC=C(N)C(C#N)=C1 BUXRLJCGHZZYNE-UHFFFAOYSA-N 0.000 claims 2
- MPCPSVWSWKWJLO-UHFFFAOYSA-N 4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenol Chemical compound CC(C)NCC(O)C1=CC=C(O)C=C1 MPCPSVWSWKWJLO-UHFFFAOYSA-N 0.000 claims 2
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 2
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 claims 2
- VPMWDFRZSIMDKW-YJYMSZOUSA-N Salmefamol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 VPMWDFRZSIMDKW-YJYMSZOUSA-N 0.000 claims 2
- ZSTCZWJCLIRCOJ-DGCLKSJQSA-N Zilpaterol Chemical compound O[C@H]1[C@H](NC(C)C)CCN2C(=O)NC3=CC=CC1=C32 ZSTCZWJCLIRCOJ-DGCLKSJQSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 2
- 229950004242 amiterol Drugs 0.000 claims 2
- RDUHXGIIUDVSHR-UHFFFAOYSA-N bamethan Chemical compound CCCCNCC(O)C1=CC=C(O)C=C1 RDUHXGIIUDVSHR-UHFFFAOYSA-N 0.000 claims 2
- 229960004162 bamethan Drugs 0.000 claims 2
- 229960001386 carbuterol Drugs 0.000 claims 2
- KEMXXQOFIRIICG-UHFFFAOYSA-N carbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(NC(N)=O)=C1 KEMXXQOFIRIICG-UHFFFAOYSA-N 0.000 claims 2
- 229950010971 cimaterol Drugs 0.000 claims 2
- 229960001117 clenbuterol Drugs 0.000 claims 2
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 claims 2
- 229950010161 deterenol Drugs 0.000 claims 2
- 239000000839 emulsion Substances 0.000 claims 2
- 229950002456 etafedrine Drugs 0.000 claims 2
- IRVLBORJKFZWMI-JQWIXIFHSA-N etafedrine Chemical compound CCN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 IRVLBORJKFZWMI-JQWIXIFHSA-N 0.000 claims 2
- LENNRXOJHWNHSD-UHFFFAOYSA-N ethylnorepinephrine Chemical compound CCC(N)C(O)C1=CC=C(O)C(O)=C1 LENNRXOJHWNHSD-UHFFFAOYSA-N 0.000 claims 2
- 229960002267 ethylnorepinephrine Drugs 0.000 claims 2
- 229950009061 flerobuterol Drugs 0.000 claims 2
- 239000006260 foam Substances 0.000 claims 2
- 229960002848 formoterol Drugs 0.000 claims 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 2
- OXLZNBCNGJWPRV-UHFFFAOYSA-N hexoprenaline Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1 OXLZNBCNGJWPRV-UHFFFAOYSA-N 0.000 claims 2
- 229960001268 isoetarine Drugs 0.000 claims 2
- JSJCTEKTBOKRST-UHFFFAOYSA-N mabuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(C(F)(F)F)=C1 JSJCTEKTBOKRST-UHFFFAOYSA-N 0.000 claims 2
- 229950004407 mabuterol Drugs 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229960002748 norepinephrine Drugs 0.000 claims 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 2
- 239000007764 o/w emulsion Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229960002288 procaterol Drugs 0.000 claims 2
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 claims 2
- 229950001879 salmefamol Drugs 0.000 claims 2
- 208000011834 subacute cutaneous lupus erythematosus Diseases 0.000 claims 2
- 229960000195 terbutaline Drugs 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 229960000960 zilpaterol Drugs 0.000 claims 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 1
- NUBLQEKABJXICM-FQEVSTJZSA-N (1r)-1-(4-amino-3,5-dichlorophenyl)-2-[6-(2-pyridin-2-ylethoxy)hexylamino]ethanol Chemical compound C1=C(Cl)C(N)=C(Cl)C=C1[C@@H](O)CNCCCCCCOCCC1=CC=CC=N1 NUBLQEKABJXICM-FQEVSTJZSA-N 0.000 claims 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical group CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 claims 1
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 claims 1
- RTLJQOLVPIGICL-UHFFFAOYSA-N 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(methylsulfonylmethyl)phenol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CS(C)(=O)=O)=C1 RTLJQOLVPIGICL-UHFFFAOYSA-N 0.000 claims 1
- KOTMQCNDGLTIHR-UHFFFAOYSA-N 4-[2-[[4-(benzimidazol-1-yl)-2-methylbutan-2-yl]amino]-1-hydroxyethyl]-3-fluorophenol Chemical compound C1=NC2=CC=CC=C2N1CCC(C)(C)NCC(O)C1=CC=C(O)C=C1F KOTMQCNDGLTIHR-UHFFFAOYSA-N 0.000 claims 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims 1
- RSDQHEMTUCMUPQ-UHFFFAOYSA-N 5-[1-hydroxy-2-(propan-2-ylamino)ethyl]quinolin-8-ol Chemical compound C1=CC=C2C(C(O)CNC(C)C)=CC=C(O)C2=N1 RSDQHEMTUCMUPQ-UHFFFAOYSA-N 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000006802 Lupus erythematosus panniculitis Diseases 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000011830 chronic cutaneous lupus erythematosus Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 229960001022 fenoterol Drugs 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 150000002337 glycosamines Chemical class 0.000 claims 1
- 150000004678 hydrides Chemical group 0.000 claims 1
- 229960004078 indacaterol Drugs 0.000 claims 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 claims 1
- 229940039009 isoproterenol Drugs 0.000 claims 1
- 239000011499 joint compound Substances 0.000 claims 1
- 229940040145 liniment Drugs 0.000 claims 1
- 239000000865 liniment Substances 0.000 claims 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- HHRNQOGXBRYCHF-UHFFFAOYSA-N n-[2-hydroxy-5-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide Chemical compound CC(C)NCC(O)C1=CC=C(O)C(NS(C)(=O)=O)=C1 HHRNQOGXBRYCHF-UHFFFAOYSA-N 0.000 claims 1
- 229950008345 nardeterol Drugs 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 229960002657 orciprenaline Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229950004618 picumeterol Drugs 0.000 claims 1
- 229950000298 quinprenaline Drugs 0.000 claims 1
- 229960002720 reproterol Drugs 0.000 claims 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 229950010289 soterenol Drugs 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229950007862 sulfonterol Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229940041677 topical spray Drugs 0.000 claims 1
- 229960000859 tulobuterol Drugs 0.000 claims 1
- 239000007762 w/o emulsion Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200500529 | 2005-04-13 | ||
| DKPA200500529 | 2005-04-13 | ||
| PCT/DK2006/050013 WO2006108424A2 (en) | 2005-04-13 | 2006-04-12 | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008535873A JP2008535873A (ja) | 2008-09-04 |
| JP2008535873A5 true JP2008535873A5 (enExample) | 2009-05-28 |
| JP5021621B2 JP5021621B2 (ja) | 2012-09-12 |
Family
ID=36703472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008505738A Expired - Fee Related JP5021621B2 (ja) | 2005-04-13 | 2006-04-12 | 皮膚の結合組織病を治療するためのβ−２アドレナリン受容体作動薬 |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US8426475B2 (enExample) |
| EP (1) | EP1719507B1 (enExample) |
| JP (1) | JP5021621B2 (enExample) |
| KR (1) | KR101355422B1 (enExample) |
| CN (1) | CN101203214B (enExample) |
| AR (1) | AR054249A1 (enExample) |
| AT (1) | ATE473735T1 (enExample) |
| AU (1) | AU2006233502B2 (enExample) |
| BR (1) | BRPI0609361A2 (enExample) |
| CA (1) | CA2604758C (enExample) |
| CY (1) | CY1111541T1 (enExample) |
| DE (1) | DE602006015387D1 (enExample) |
| DK (1) | DK1719507T3 (enExample) |
| EA (1) | EA016082B1 (enExample) |
| ES (1) | ES2348920T3 (enExample) |
| HR (1) | HRP20100552T1 (enExample) |
| IL (1) | IL186491A (enExample) |
| MX (1) | MX2007012794A (enExample) |
| MY (1) | MY147864A (enExample) |
| NO (1) | NO331211B1 (enExample) |
| NZ (1) | NZ562940A (enExample) |
| PL (1) | PL1719507T3 (enExample) |
| PT (1) | PT1719507E (enExample) |
| RS (1) | RS51464B (enExample) |
| SI (1) | SI1719507T1 (enExample) |
| TW (1) | TWI366457B (enExample) |
| WO (1) | WO2006108424A2 (enExample) |
| ZA (1) | ZA200708748B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0604826D0 (en) * | 2006-03-09 | 2006-04-19 | Arakis Ltd | The treatment of inflammatory disorders and pain |
| MX2009000382A (es) | 2006-07-10 | 2009-01-27 | Intervet Int Bv | Composiciones de enantiomero zilpaterol y metodos para elaborar y usar tales composiciones. |
| GB0624757D0 (en) * | 2006-12-12 | 2007-01-17 | Sosei R & D Ltd | Novel compounds |
| GB0805535D0 (en) | 2008-03-27 | 2008-04-30 | Univ Leicester | Scar prevention |
| US20120252831A1 (en) * | 2011-03-31 | 2012-10-04 | Mustafa Nevzat Ilac Sanayii A.S. | Compositions of opioid antagonists and methods for treating scleroderma therewith |
| CN102267917B (zh) * | 2011-06-15 | 2013-07-31 | 浙江工业大学 | 一种盐酸甲氧那明的合成方法 |
| UA115445C2 (uk) * | 2012-05-18 | 2017-11-10 | Інтервет Інтернешнл Б.В. | Спосіб збільшення приросту бройлерних курей |
| GB2513297A (en) * | 2013-03-08 | 2014-10-29 | Univ Leicester | Methods |
| CN104606177B (zh) * | 2014-11-21 | 2018-02-02 | 苏州君宁新药开发中心有限公司 | 左旋(r)沙丁胺醇制剂在治疗皮肤及粘膜创伤溃疡的药物应用 |
| WO2018000098A1 (en) * | 2016-06-30 | 2018-01-04 | Cipher Pharmaceuticals Inc. | Treatment of inflammatory myopathies |
| CN106580978A (zh) * | 2016-11-30 | 2017-04-26 | 郑州仁宏医药科技有限公司 | 一种治疗皮炎的西药组合物及其应用 |
| US10576043B2 (en) * | 2017-08-10 | 2020-03-03 | Avro Life Sciences, Inc. | Transdermal drug delivery system |
| GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201903832D0 (en) | 2019-03-20 | 2019-05-01 | Atrogi Ab | New compounds and methods |
| US10947196B2 (en) * | 2019-03-27 | 2021-03-16 | Curasen Therapeutics, Inc. | Beta adrenergic agonist and methods of using the same |
| US11607395B2 (en) | 2019-12-18 | 2023-03-21 | Curasen Therapeutics, Inc. | Methods for improving neurological diseases and disorders |
| CN112300237A (zh) * | 2020-04-13 | 2021-02-02 | 苏州恩泰新材料科技有限公司 | 海豹胆酸的制备方法及其应用 |
| BR112023005697A2 (pt) * | 2020-10-09 | 2023-04-25 | Mc2 Therapeutics Ltd | Tratamento de condições dermatológicas |
| US20240043499A1 (en) | 2022-08-07 | 2024-02-08 | Protean Bio, Inc. | Peptides for beta-cell survival and insulin production |
| CN116236467B (zh) * | 2023-02-07 | 2023-10-27 | 中国人民解放军总医院 | 西马特罗或其衍生物的新用途 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA7464B (en) | 1973-01-16 | 1974-11-27 | J Voorhees | Treatment of proliferating skin diseases with papavine alkaloids |
| US4284623A (en) * | 1979-11-09 | 1981-08-18 | Beck Lee R | Method of treating inflammation using bovine milk |
| SU895445A1 (ru) * | 1980-05-15 | 1982-01-07 | Военно-Медицинская Краснознаменная Академия Им. С.М.Кирова | Способ лечени кожных форм красной волчанки |
| US4574129A (en) | 1984-01-31 | 1986-03-04 | Bristol-Myers Company | Topical nonsteroidal anti-inflammatory methods |
| JPS61154201A (ja) | 1984-12-26 | 1986-07-12 | Matsushita Electric Ind Co Ltd | 誘電体フイルタ |
| US4699777A (en) | 1985-08-21 | 1987-10-13 | Schering Corporation | Compositions and method for enhancement of the transdermal flux of albuterol with a combination of 1-dodecyl-azacyclopheptan-2-one and urea |
| PH25150A (en) | 1986-06-05 | 1991-03-13 | Ciba Geigy Ag | Novel pharmaceutical preparation for topical application |
| US4980159A (en) | 1989-05-23 | 1990-12-25 | Bristol-Myers Squibb Company | Processes and compositions for the topical application of β-adrenergic agonists for pilomotor effects |
| RU2092105C1 (ru) * | 1989-11-20 | 1997-10-10 | Нижегородский научно-исследовательский кожно-венерологический институт | Способ определения терапевтической тактики у больных очаговой склеродермией и дискоидной красной волчанкой |
| DE4014252A1 (de) * | 1990-05-04 | 1991-11-07 | Boehringer Ingelheim Vetmed | Enantiomerentrennung von cimaterol, (-)-cimaterol und dessen verwendung als arzneimittel oder als leistungsfoerderer |
| US5919827A (en) | 1990-07-11 | 1999-07-06 | Sepracor Inc. | Method for treating asthma using optically pure R(-) salmeterol |
| ES2084825T3 (es) | 1990-07-26 | 1996-05-16 | Monsanto Co | Procedimiento de preparacion de poliamidas entrecruzadas. |
| US5795564A (en) | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| GB9107196D0 (en) * | 1991-04-05 | 1991-05-22 | Sandoz Ag | Improvements in or relating to organic compounds |
| JP3294876B2 (ja) | 1992-07-20 | 2002-06-24 | トキコ株式会社 | 給油装置 |
| WO1995019336A1 (de) | 1994-01-12 | 1995-07-20 | Iovis Biomedical And Pharmaceutical Consultants | Phenylethanolaminether und ihre verwendung als beta-adrenorezeptor-agonisten |
| JPH07304647A (ja) | 1994-05-09 | 1995-11-21 | Kao Corp | マッサージ用組成物 |
| GB9422306D0 (en) * | 1994-11-04 | 1994-12-21 | Sandoz Ltd | Organic compounds |
| GB9510162D0 (en) * | 1995-05-19 | 1995-07-12 | Bouras Elias | Compositions for the treatment of skin conditions |
| JPH09110674A (ja) | 1995-10-16 | 1997-04-28 | Kao Corp | 浴用剤組成物 |
| FR2740040B1 (fr) | 1995-10-23 | 1997-12-05 | Oreal | Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p |
| EP0979081A4 (en) * | 1997-04-30 | 2003-05-02 | Bridge Pharma Inc | COMPOSITION AND METHODS USING EUTOMER |
| US6254882B1 (en) | 1997-09-16 | 2001-07-03 | Sepracor Inc. | Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol |
| WO2002018395A1 (en) * | 2000-08-31 | 2002-03-07 | Merck & Co., Inc. | Phosphate derivatives as immunoregulatory agents |
| WO2002040021A2 (en) | 2000-11-17 | 2002-05-23 | Idenix (Cayman) Limited | Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines |
| HUP0402577A3 (en) | 2001-12-03 | 2011-05-30 | Wyeth Corp | Indole derivatives as inhibitors of cytosolic phospholipase a2, process for producing them and pharmaceutical compositions containing them |
| CN1646143A (zh) * | 2002-04-19 | 2005-07-27 | 艾升发展公司 | β－2肾上腺素受体兴奋剂与氨基糖的结合及其在治疗免疫功能紊乱方面的应用 |
| AU2003228133A1 (en) | 2002-04-22 | 2003-11-03 | Umc Utrecht Holding B.V. | Reduction of unwanted immune reactions |
| WO2003092617A2 (en) | 2002-05-03 | 2003-11-13 | Combinatorx, Incorporated | Combinations for the treatment of inflammatory skin disorders |
| DE10224888A1 (de) | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
| US20040229849A1 (en) | 2002-09-24 | 2004-11-18 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| US20040220153A1 (en) * | 2002-09-24 | 2004-11-04 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| EP1553955A4 (en) * | 2002-09-24 | 2008-11-05 | Combinatorx Inc | METHODS AND REAGENTS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH INCREASED LEVELS OF PRO-INFLAMMATORY CYTOKINES |
| ES2401079T3 (es) | 2002-12-20 | 2013-04-16 | Amgen Inc. | Moduladores del asma y de la inflamación alérgica |
| TW200902047A (en) * | 2003-02-14 | 2009-01-16 | Combinatorx Inc | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| US20040209850A1 (en) * | 2003-04-15 | 2004-10-21 | Theraquest Biosciences, Llc | Methods of treating pain and compositions for use therefor |
| EP1646370A1 (en) | 2003-07-11 | 2006-04-19 | Glaxo Group Limited | Pharmaceutical formulations |
| TW200522932A (en) | 2003-09-15 | 2005-07-16 | Combinatorx Inc | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| JP2007512337A (ja) * | 2003-11-21 | 2007-05-17 | コンビナトアールエックス インコーポレーティッド | 炎症性障害の治療のための方法および試薬 |
| WO2005089741A2 (en) | 2004-03-17 | 2005-09-29 | Sosei R&D Ltd. | The treatment of inflammatory disorders and pain using beta-aminoalcohols |
| WO2005102296A2 (en) | 2004-04-23 | 2005-11-03 | Heptagen Limited | Combinations for the treatment of immunoproliferative skin disorders such as psoriasis |
| EP1786410A2 (en) * | 2004-09-07 | 2007-05-23 | Sosei R&D Ltd. | The treatment of inflammatory disorders and pain |
-
2006
- 2006-04-12 WO PCT/DK2006/050013 patent/WO2006108424A2/en not_active Ceased
- 2006-04-12 CA CA2604758A patent/CA2604758C/en not_active Expired - Fee Related
- 2006-04-12 AR AR20060101443A patent/AR054249A1/es not_active Application Discontinuation
- 2006-04-12 KR KR1020077026406A patent/KR101355422B1/ko not_active Expired - Fee Related
- 2006-04-12 EP EP06007632A patent/EP1719507B1/en not_active Expired - Lifetime
- 2006-04-12 DE DE602006015387T patent/DE602006015387D1/de not_active Expired - Lifetime
- 2006-04-12 ES ES06007632T patent/ES2348920T3/es not_active Expired - Lifetime
- 2006-04-12 BR BRPI0609361-2A patent/BRPI0609361A2/pt not_active Application Discontinuation
- 2006-04-12 RS RSP-2010/0442A patent/RS51464B/sr unknown
- 2006-04-12 PT PT06007632T patent/PT1719507E/pt unknown
- 2006-04-12 TW TW095112980A patent/TWI366457B/zh not_active IP Right Cessation
- 2006-04-12 SI SI200630807T patent/SI1719507T1/sl unknown
- 2006-04-12 AT AT06007632T patent/ATE473735T1/de active
- 2006-04-12 NZ NZ562940A patent/NZ562940A/en not_active IP Right Cessation
- 2006-04-12 AU AU2006233502A patent/AU2006233502B2/en not_active Ceased
- 2006-04-12 CN CN2006800165347A patent/CN101203214B/zh not_active Expired - Fee Related
- 2006-04-12 JP JP2008505738A patent/JP5021621B2/ja not_active Expired - Fee Related
- 2006-04-12 MX MX2007012794A patent/MX2007012794A/es active IP Right Grant
- 2006-04-12 EA EA200702204A patent/EA016082B1/ru not_active IP Right Cessation
- 2006-04-12 US US11/402,255 patent/US8426475B2/en not_active Expired - Fee Related
- 2006-04-12 MY MYPI20061656A patent/MY147864A/en unknown
- 2006-04-12 PL PL06007632T patent/PL1719507T3/pl unknown
- 2006-04-12 DK DK06007632.0T patent/DK1719507T3/da active
-
2007
- 2007-10-08 IL IL186491A patent/IL186491A/en active IP Right Grant
- 2007-10-12 ZA ZA200708748A patent/ZA200708748B/xx unknown
- 2007-11-02 NO NO20075527A patent/NO331211B1/no not_active IP Right Cessation
-
2010
- 2010-10-11 HR HR20100552T patent/HRP20100552T1/hr unknown
- 2010-10-14 CY CY20101100919T patent/CY1111541T1/el unknown
-
2013
- 2013-04-22 US US13/867,796 patent/US20130237607A1/en not_active Abandoned
-
2017
- 2017-02-23 US US15/440,803 patent/US9907765B2/en not_active Expired - Fee Related
-
2018
- 2018-12-21 US US16/228,920 patent/US20190125699A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9907765B2 (en) | Treatment of connective tissue diseases of the skin | |
| US20110224196A1 (en) | Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent | |
| JP2009542657A5 (enExample) | ||
| JP2018199684A5 (enExample) | ||
| RU2019100425A (ru) | Новая доза и препаративная форма | |
| EP3551166B1 (en) | Topical phenytoin for use in the treatment of peripheral neuropathic pain | |
| WO2011050728A1 (zh) | 一种稳定的雷沙吉兰组合物 | |
| EP3796907A1 (en) | Gabaa positive allosteric modulator compounds for treatment of itch and/ or dermatitis | |
| RU2008110933A (ru) | Применение амброксола для лечения риновирусных инфекций | |
| EP3463334B1 (en) | Compositions and methods for protecting organs from ischemia/reperfusion injury associated with transplantation | |
| TWI856977B (zh) | 胺基甲酸酯化合物及包括該化合物之組合於預防、緩解或治療急性壓力症或創傷後壓力症之用途 | |
| CN101757078B (zh) | 一种用于治疗腮腺炎的复方巴布剂及其制备方法 | |
| KR20070059079A (ko) | 경피 페로스피론 투여용 의약적 조성물 | |
| KR20120102214A (ko) | 한방복합 생약 소염 진통 외용제 | |
| JP5469779B2 (ja) | 多発性骨髄腫の治療のための組成物および方法 | |
| EP2736501B1 (en) | Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol | |
| HK1091739B (en) | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin | |
| Szycher | Recent advances in transdermal delivery systems | |
| JPH0211566B2 (enExample) | ||
| WO2018000098A1 (en) | Treatment of inflammatory myopathies |